All sequences were verified by sequencing. pcDNA3.1/RASSF1A-expression vector 131 was a kind gift from Reinhard Dammann (Justus-Liebig University, Giessen, 132
Germany). 133 134

Luciferase reporter assay 135
To prove the direct binding of miR-181a/b to the 3'UTR of RASSF1A mRNA, U937 136 cells were transiently cotransfected with 0.5 µg of each reporter construct (pGL3-137 control vector, pGL3/3´UTR-RASSF1A and pGL3/3´UTR-RASSF1A-mutated), 0.1µg 138 of Renilla construct (pRL) and 1 µM miR-181a, miR-181b mimics or control mimics 139 using amaxa technology (Lonza). Luciferase activities were determined 24 hours 140 after transfection using the Dual-Luciferase Reporter Assay System (Promega). 141
Values were normalized using Renilla luciferase. 
Cell growth assay 157
NB4 cells stably transduced with pmiR-ZIP-181a, pmiR-ZIP-181b or control-vector 158
were plated in a density of 1 x 10 4 cells/ml. Proliferation rate was ascertained by cell 159 counting in a Neubauer camber using Trypan blue-staining for excluding death cells. 160
161
Clonogenic assay 162
NB4 cells stably expressing anti-miR-181a, anti-miR-181b or an unspecific control 163 sequence were seeded in a density of 1 x 10 3 cells/ml in methylcellulose based 164 media (MethoCult H4230; StemCell Technologies) as triplicates according to the 165 manufacturer's instructions. Replating was done after 6 days and repeated 3 times. 166
Colony numbers were evaluated after each plating by standard criteria. For colony 167 size measurement pictures were taken randomly from each condition and a total 168 number of 135 colonies were measured by using ImageJ software. Total RNA was extracted using Trizol. MiRNA quantification was performed as 172 previously described by using hsa-miR-181a and hsa-miR-181b primer sets or mmu-173 miR-181a and mmu-miR-181b-1 primer sets (Applied BiosystemsInc.,CA, USA). 174
Normalization was done by measuring RNU6B (U6) expression and small nuclear 175 RNA135 (snoR135) expression. mRNA amplification was performed as previously 176 described by using glycerinaldehyde-3-phosphate dehydrogenase (GAPDH) 177 expression for normalization (11). Primer sequences are provided in Supplementary 178 
Immunoblot analysis 183
Immunoblot analysis was performed as previously described (11 Lincoln, NE, USA). Band intensities were quantified using Image J software (National 193
Institutes of Health). 194 195
Flow cytometry 196
Cell differentiation was evaluated by direct immunofluorescence staining using 197 
Statistical analysis 209
We used the Student t test to determine statistical significance of experimental 210 results. A p-value of 0.05 or less was considered significant (*) and a p-value of 0.01 211 or less were considered as highly significant (**). The results were represented as 212 the median plus or minus Standard deviation (SD) from 3 independent experiments 213 for cell line experiments and from 2 independent reverse transcription and 214 quantitative PCR (qPCR) analysis for primary cell samples. 215
216
Results
217
ATRA-treatment represses miR-181 family member expression in APL cell line 218 and in APL patients 219
Several studies show the modulation of microRNA pattern upon ATRA-treatment 220 (10,14,19). We analyzed miR-181 family member expression (miR-181a-d) 24h after 221 ATRA-treatment and observed a significantly downregulation of all miR-181 family 222 members (Fig. 1A) . The genomically clustered miR-181a and miR-181b show similar 223 expression levels, whereas miR-181c and miR-181d, also organized in a genomic 224 cluster, were differentially expressed (20). MiR-223 expression was used as 225 experimental control and showed a 2-fold upregulation (Fig. 1B) . 226
Furthermore, we induced granulocytic differentiation by ATRA in NB4 cells and the 227 non-APL cell lines U937 and HL60. Differentiation was confirmed by CD11b 228 measurement (Fig. 1C,E,G) . NB4 cells showed a significant reduction of miR-181a/b 229 expression over time (Fig. 1D) . No significant change of miR-181a/b expression 230 could be observed in U937 (Fig. 1F ) and HL60 cells (Fig. 1H) . trioxide in constrast to ATRA which strongly reduced the microRNA expression (Fig  237   1I, J) . 7-AAD/Annexin V measurement revealed strong induction of apoptosis by 238 cytostatics and As 2 O 3 . CD11b cell surface marker and C/EBPβ mRNA were slightly 239 and only temporary induced by As 2 O 3 or cytostatics compared to ATRA which 240 strongly induced granulopoiesis ( Supplementary Fig. S1 ). Furthermore, we used 241 samples from APL patients which received a combination of ATRA with 242 chemotherapy to investigate the expression of miR-181a/b. Analysis was performed 243 at time point of diagnosis and at one time point during therapy (Supplementary Table  244 S1). In all 6 analyzed patients we observed a highly significant repression of miR-245 181a/b expression in consequence to ATRA-based therapy (Fig. 1K,L) . Fig. 2A) . The control cell line U937-PC18 showed no significant change in 254 microRNA expression after ZnSO 4 application (Fig. 2B) . Additionally, we analyzed 255 bone marrow samples from PML/RARα knock-in mice and wild type animals 256 (C57BI/6-WT); (17). We observed a significant enhanced expression of murine miR-257 181a/b in PML/RARα knock in mouse samples in comparison to wild type samples 258 (Fig. 2C) . Furthermore, we analyzed bone marrow samples from patients with 259 different AML subtypes and blood cell samples from healthy donors. The results 260 showed significantly higher miR-181a/b expression values in APL patient samples 261 compared to the samples with normal karyotype whereas all other analyzed samples 262
showed no significant microRNA expression change (Supplementary Table S2 ; Fig.  263   2D) . 264
265
The miR-181a/b-cluster is necessary for proliferation, induces apoptosis and 266
inhibits granulocytic differentiation of APL cells 267
To address the role of miR-181a/b in APL in detail, we stably knocked down both 268 microRNAs in NB4 cells by using miR-ZIP-lentiviral particles. Knock down efficiency 269 was verified by qPCR (Fig. 3A) . The PML/RARα fusion protein promotes cell survival 270 (4). To evaluate a potential role for miR-181a and miR-181b in this process, we 271 examined an apoptosis assay. Knockdown of miR-181a and miR-181b results in 272 significantly increased apoptosis ( miR-181b to the 3´UTR of RASSF1A, we generated a luciferase construct containing 304 the complete 3´UTR of RASSF1A and mutated the binding sites ( Fig. 4D,E) . 305
Reporter assay showed repression of luciferase activity after miR-181a and miR-306 (Fig. 4G) . Additionally, RASSF1A protein was increased after miR-ZIP-313 mediated knockdown of miR-181a and miR-181b in NB4 cells compared to the 314 control cells (Fig. 4H) . 315
316
RASSF1A protein is specifically suppressed in APL 317
RASSF1A is shown to be an important regulator of cell differentiation in a wide range 318 of cell types (22) by exercising its functions as a modulator of two pathways 319 commonly deregulated in cancer, apoptosis, and cell cycle (24,25). Therefore, we 320
hypothesize that RASSF1A could function as tumor suppressor in APL, where 321 PML/RARα causes oncogenic transformation by deregulating cell cycle and 322
apoptosis (4). 323
Western blot analysis of bone marrow samples from patients with different AML 324 subtypes and blood cell samples from healthy donors showed significant lower 325 amounts of RASSF1A protein in APL patients compared to AML patients with normal 326 karyotype (Supplementary Table S2 ; Fig. 5A ). No significant change in RASSF1A 327 protein levels could be observed in other AML subtypes and in non-AML samples. 328
Interestingly, RASSF1A mRNA exhibited a heterogeneous distribution and especially 329 no reduction in t(15;17), (Fig. 5B) . Furthermore, we observed significant lower 330 RASSF1A protein levels in PML/RARα knock-in mice (C57BI/6-mCG
to wild type animals (C57BI/6-WT), (Fig. 5C) . (Fig. 7B) . We also performed cell cycle analysis 24h after ATRA-358 treatment of RASSF1A shRNA expressing NB4 cells and observed that shRNA 359 mediated knockdown of RASSF1A leads to a marked reduction in G1/G0-phase and 360 an increase in the S-and G2-phase in comparison to the control shRNA expressing 361 cells (Fig. 7C) . Additionally, we analyzed cell cycle in miR-ZIP-181a and miR-ZIP-362 181b expressing NB4 cells. The results showed that knockdown of miR-181a and 363 miR-181b reduces S-and G2-phase and increases G1/G0-phase as well as SubG1- (Fig. 7D) . To show the regulatory impact of miR-181a and miR-181b on cyclin 365 D1, we transiently transfected miR-181a and miR-181b mimics in U937 cells. 366
Western blot showed an elevated protein level of cyclin D1 48h after single or 367 combined miR-181a and miR-181b mimic transfection compared to the control (Fig.  368   7E) . (Fig. 7F) . 374
375
Discussion 376
A rising number of studies have shown the importance of microRNAs in the formation 377 and maintenance of leukemia. In this report, we demonstrate that ATRA is able to 378 significantly downregulate the expression of the whole miR-181 family in APL (Fig.  379   1A) . We show the constant downregulation of the miR-181a/b-cluster upon ATRA-380 treatment over time in APL in vitro and in vivo (Fig. 1D,K,L) . Furthermore, we 381 demonstrate that cytostatics and arsenic trioxide which are typically used in APL 382 therapy and predominately inducers of apoptosis does not affect miR-181a/b 383 expression ( Figure 1I,J) . These results expand and confirm previous observations 384 (10,14-16) and suggest a specific role for the miR-181 family in the response to 385 ATRA in APL. Diverse publications illustrate the expression pattern and define 386 multiple functions for miR-181a and miR-181b in hematopoiesis and leukemia, 387 whereas miR-181c and miR-181d are less described (8,27-31). The fact that ATRA 388 leads to the degradation of PML/RARα and thereby changes gene expression let 389 assume that miR-181a/b expression is dependent on PML/RARα (1). We followed 390 (Fig. 1E,G,F,H) . This observation substantiates the proposed 393 PML/RARα-dependency of miR-181a/b expression. 394
The miR-181a/b-cluster has been shown to be upregulated in AML patients with 395 C/EBPα-mutations which have a favorable prognosis and to be associated with 396 favorable outcome in patients with cytogenetically normal AML and cytogenetically 397 abnormal AML (32-34). Combining these data, high expression of miR-181a and 398 miR-181b occurs in combination with a favorable outcome of AML. In APL, a 399 combination of ATRA and arsenic trioxide therapy generates a complete remission 400 rate (CR) of over 90% (35). Our observation that the miR-181a/b-cluster is highly 401 expressed in APL and significantly downregulated upon ATRA-treatment in vitro and 402 in vivo points to a role for the microRNA cluster as prognostic marker in t(15;17). 403
Beside its function as transcriptional repressor (2), PML/RARα is also able to induce 404 transcription, whereas this effect seems to be indirect due the sequestration of 405 corepressors (36). In this study, we demonstrate the PML/RARα-dependent 406 upregulation of miR-181a/b in PR9 cells and in PML/RARα knock-in mice (Fig. 2 A-407 C). Additionally, we show significantly higher expression of the miR-181a/b-cluster in 408 bone marrow samples from APL patients (Fig. 2D) . Diverse publications describe miR-181 family members as either oncogenes or tumor 416 suppressors in various cancers depending on tissue type (37-40). The fact that miR-417 181a/b expression is significantly high in t(15;17) let assume that both microRNAs 418 are involved in the formation of the oncogenic phenotype caused by PML/RARα. Our 419 functional studies show that ectopic expression of miR-181a and miR-181b 420 effectively blocks ATRA-induced granulocytic differentiation (Fig. 3F,G) and that 421 inhibition of the miR-181a/b-cluster effectively represses cell proliferation and 422 induces apoptosis in APL cells (Fig. 3A-E) . In contrast to data from Hickey et al. (Fig. 1A,D,K,L and Fig. 4A) . Additionally, we demonstrate that RASSF1A 440 (Fig. 4B, Fig. 1I and J) . Finally, we prove by luciferase assay that 442 repression of RASSF1A protein occurs via direct binding of miR-181a and miR-181b 443 to its 3´UTR (Fig. 4F) (Fig. 4F,G,H) . Furthermore, we observed the APL specific 448 inverse correlation of miR-181a/b expression and RASSF1A protein which could not 449 be seen in the other analyzed AML subgroups and healthy donors. The proposed 450 specificity of RASSF1A suppression by a PML/RARα-dependent mechanism is 451 supported by protein expression data in AML patient samples and in PML/RARα 452 knock-in mice, which show reduced RASSF1A protein levels when the miR-181a/b-453 cluster is highly expressed (Fig. 2C,D suppressor function of RASSF1A in APL (Fig. 6C) . Additionally, reduced granulocytic 462 differentiation of NB4 cells in consequence to RASSF1A knockdown supports the 463 proposed differentiation associated function of RASSF1A (Fig. 6B) . It was shown that 464 RASSF1A is able to effectively prevent G1/S-phase transition by blocking cyclin D1 465 CAN-14-3521 process involves the sequential regulation of cell-cycle regulatory proteins, such as 468 cyclin D1, which promotes G1-S progression (49). In our study, we confirm the 469 ATRA-induced repression of cyclin D1 in APL cells ( Figure 7A ). We also show that 470 overexpression of RASSF1A leads to a dramatic repression of cyclin D1 protein and 471 that knockdown of RASSF1A promotes cell cycle progress in APL (Fig. 7B, C) . 472
Furthermore, we could demonstrate that RASSF1A is the key mediator for miR-181a 473 and miR-181b mediated induction of cyclin D1 accompanied by cell cycle 474 progression in APL (Fig. 7E,F) . Finally, in contrast to ATRA, arsenic trioxide which 475 induces apoptosis in APL does not affect miR-181a/b expression and RASSF1A 476
protein. This correlates with the finding that arsenic trioxide does not donwregulate 477 cyclin D1 protein (50). Based on these findings, we claim RASSF1A as an important 478 factor in the granulocytic differentiation, which prevents cyclin D1 accumulation, cell 479 cycle progress and promotes differentiation upon ATRA-treatment in APL blasts. 480
In summary, our study highlights the clustered miR-181a and miR-181b as important 481 factors in the PML/RARα-associated APL. To the best of our knowledge, we are the 482 first describing the miR-181a/b target RASSF1A as an essential member of the 483 ATRA-induced granulocytic differentiation network in APL (Fig. 7G) 
